Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Etonogestrel implant is a long-acting, reversible contraceptive device containing 68 mg of the synthetic progestin hormone etonogestrel. It is supplied as a small, flexible plastic rod that is inserted subdermally into the inner side of the upper arm by a healthcare provider. The implant provides continuous contraception for up to three years by slowly releasing etonogestrel into the bloodstream. Its primary mechanism of action is inhibition of ovulation through suppression of luteinizing hormone release; it also thickens cervical mucus to impede sperm penetration and alters endometrial lining to reduce likelihood of implantation. Etonogestrel implants are highly effective (failure rate ~0.1%) and fertility typically returns rapidly after removal[2][3][4][5][6][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on etonogestrel implant.